Effects of Rofecoxib or Naproxen vs Placebo on Alzheimer Disease Progression
Top Cited Papers
Open Access
- 4 June 2003
- journal article
- clinical trial
- Published by American Medical Association (AMA) in JAMA
- Vol. 289 (21) , 2819-2826
- https://doi.org/10.1001/jama.289.21.2819
Abstract
Alzheimer disease (AD) is among the most important health problems of elderly persons, affecting more than 4 million people in the United States. In the last decade, cholinesterase inhibitors have been widely used to alleviate symptoms of cognitive dysfunction in AD. The use of anti-inflammatory drugs is among the strategies under active investigation for the development of effective disease-modifying treatment for AD. This approach is supported by a wealth of laboratory evidence that inflammatory mechanisms contribute to neuronal damage in AD.1 Furthermore, many epidemiological studies suggest that anti-inflammatory drugs have a protective effect, reducing the incidence of AD.2Keywords
This publication has 26 references indexed in Scilit:
- Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's Disease neuropathologyNeurobiology of Aging, 2002
- Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic miceNeurobiology of Aging, 2001
- Inflammation, autotoxicity and Alzheimer diseaseNeurobiology of Aging, 2001
- A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activityNature, 2001
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisNew England Journal of Medicine, 2000
- An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs DiseaseAlzheimer Disease & Associated Disorders, 1997
- Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's diseaseNeurology, 1996
- The Clinical Dementia Rating (CDR)Neurology, 1993
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984
- “Mini-mental state”Journal of Psychiatric Research, 1975